Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Short hairpin RNA (shRNA) targeting CARHSP1 is an experimental RNA interference (RNAi) agent designed to silence the expression of Calcium-regulated heat-stable protein 1 (CARHSP1). CARHSP1 is a member of the cold shock domain (CSD) protein family and functions as an RNA-binding protein (RBP) that regulates mRNA stability and translation. In the context of prostate cancer, CARHSP1 has been identified as a key driver of tumor progression by binding to and stabilizing the mRNA of Interleukin-17 Receptor A (IL-17RA). This stabilization leads to the activation of the JAK-STAT3 and NF-κB signaling pathways, which promote tumor growth, metastasis, and the upregulation of PD-L1, thereby facilitating immune escape. By specifically knocking down CARHSP1 expression, this shRNA therapy aims to destabilize IL-17RA mRNA, inhibit oncogenic signaling, and restore anti-tumor immune responses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on short hairpin RNA targeting CARHSP1.